Dr. Armstrong is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Longwood Ave
Boston, MA 02115Phone+1 617-632-3951
Education & Training
- Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 1996 - 1998
- University of Texas Southwestern Medical SchoolClass of 1996
Certifications & Licensure
- MA State Medical License 1998 - 2026
- NY State Medical License 2014 - 2016
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2010
Publications & Presentations
PubMed
- 1 citationsCRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify KDM3B as a Genotype-specific Vulnerability in IDH2- and TET2-mutant Cells.Michael R Waarts, Shoron Mowla, Meaghan Boileau, Anthony R Martinez Benitez, Junya Sango
Cancer Discovery. 2024-10-04 - 6 citationsPreclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias.Min Chul Kwon, Jan Willem Thuring, Olivier Querolle, Xuedong Dai, Tinne Verhulst
Blood. 2024-09-12 - 3 citationsA MOZ-TIF2 leukemia mouse model displays KAT6-dependent H3K23 propionylation and overexpression of a set of active developmental genes.Anne E Smolko, Daniel W Sullivan, Sarah Naomi Olsen, Hyuckjoon Kang, Samuel D Whedon
Proceedings of the National Academy of Sciences of the United States of America. 2024-06-25
Journal Articles
- Article HOXA9 Reprograms the Enhancer Landscape to Promote LeukemogenesisRoss L Levine, Jay L Hess, Sheng Cai, Scott A Armstrong, ScienceDirect
Abstracts/Posters
- Rationale for Targeting BCL6 in MLL-Rearranged B-ALLScott A. Armstrong, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Leukemia Cell of Origin Influences p53 Activity and Therapeutic Sensitivity Via an Evi1-Dependent MechanismScott A. Armstrong, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid LeukemiaScott A. Armstrong, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Biochemical and Genetic Insights Into MLL/11q23 Translocation Leukemia60th American Society of Hematology Annual Meeting - 12/2/2018
- High-Density CRISPR Scan Identifies Functional Regions of DOT1L That Mediate Therapeutic Response in MLL-r Leukemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
- Dana-Farber/Boston Children's Ranked Among the Best Pediatric Cancer Programs in the Nation for 18th Year in a RowOctober 8th, 2024
- Experimental Pill Sends a Third of Leukemia Patients into Complete Remission in an Early TrialMarch 24th, 2023
- Experimental Pill Sends a THIRD of Patients with Leukemia into Complete Remission in Early TrialMarch 24th, 2023
- Join now to see all
Grant Support
- Molecular Pathogenesis Of MLL-AF4 LeukemiasNational Cancer Institute2010–2012
- MLL Fusion Genes In Myeloid And Lymphoid LeukemiasNational Cancer Institute2008–2012
- Comprehensive Phenotypic Comparison Of Normal And Cancer Stem CellsNational Cancer Institute2009–2010
- The Core Apoptotic Pathway Controlling Glucocorticoid-Induced Apoptosis In AllNational Cancer Institute2006–2010
- MLL Gene Regulation In Hematopoiesis And LeukemiaNational Cancer Institute2005–2006
- MLL Gene Regulation In Hematopoiesis And LeukemiaNational Cancer Institute2001–2004
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: